Compugen Ltd (CGEN)
NASDAQ
$2.33−$0.0550 (−2.31%) on the dayAs of the close; data may be delayed.
CGEN price, last 12 months
Key stats
- Previous close
- $2.38
- Open
- $2.34
- Day range
- $2.32 – $2.34
- 52-week range
- $1.37 – $3.24
- Volume
- 4.2K
- Avg volume (20 days)
- 173.2K
- Market cap
- $225.5M
Performance
1W−4.5%
1M−15.8%
3M+7.6%
6M+14.0%
YTD+52.0%
1Y+68.5%
vs S&P 500, 1Y+51.8 pts
Technicals and fundamentals
About Compugen Ltd
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
- Listed on
- NASDAQ
- Market cap
- $225.5M